290 related articles for article (PubMed ID: 14576939)
1. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours.
Fraggetta F; Pelosi G; Cafici A; Scollo P; Nuciforo P; Viale G
Virchows Arch; 2003 Dec; 443(6):782-6. PubMed ID: 14576939
[TBL] [Abstract][Full Text] [Related]
2. [Expression of the cdx2 gene in benign intestinal-type mucinous ovarian tumors].
Gaggero G; Sola S; Mora M; Fulcheri E
Pathologica; 2003 Aug; 95(4):185-91. PubMed ID: 14577202
[TBL] [Abstract][Full Text] [Related]
3. Expression of REG4 in ovarian mucinous tumors.
Huang Q; Chen X; Lu W; Lai M; Lu B
Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):295-301. PubMed ID: 23958547
[TBL] [Abstract][Full Text] [Related]
4. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.
Vang R; Gown AM; Wu LS; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Mod Pathol; 2006 Nov; 19(11):1421-8. PubMed ID: 16980943
[TBL] [Abstract][Full Text] [Related]
6. The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.
Groisman GM; Meir A; Sabo E
Int J Gynecol Pathol; 2004 Jan; 23(1):52-7. PubMed ID: 14668551
[TBL] [Abstract][Full Text] [Related]
7. CDX-2 immunostaining in primary and secondary ovarian carcinomas.
Tornillo L; Moch H; Diener PA; Lugli A; Singer G
J Clin Pathol; 2004 Jun; 57(6):641-3. PubMed ID: 15166272
[TBL] [Abstract][Full Text] [Related]
8. Mucinous Ovarian Tumors.
Mills AM; Shanes ED
Surg Pathol Clin; 2019 Jun; 12(2):565-585. PubMed ID: 31097115
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours.
Strickland S; Parra-Herran C
Histopathology; 2016 Jun; 68(7):977-87. PubMed ID: 26542609
[TBL] [Abstract][Full Text] [Related]
10. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
11. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive immunohistochemical analysis of the gastrointestinal and Müllerian phenotypes of 139 ovarian mucinous cystadenomas.
Halimi SA; Maeda D; Ushiku-Shinozaki A; Goto A; Oda K; Osuga Y; Fujii T; Ushiku T; Fukayama M
Hum Pathol; 2021 Mar; 109():21-30. PubMed ID: 33275953
[TBL] [Abstract][Full Text] [Related]
13. Histochemical analysis of estrogen and progesterone receptors and gastric-type mucin in mucinous ovarian tumors with reference to their pathogenesis.
Shiohara S; Shiozawa T; Shimizu M; Toki T; Ishii K; Nikaido T; Fujii S
Cancer; 1997 Sep; 80(5):908-16. PubMed ID: 9307191
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory role of prohibitin in human ovarian epithelial cancer.
Jia L; Ren JM; Wang YY; Zheng Y; Zhang H; Zhang Q; Kong BH; Zheng WX
Int J Clin Exp Pathol; 2014; 7(5):2247-55. PubMed ID: 24966933
[TBL] [Abstract][Full Text] [Related]
15. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.
Logani S; Oliva E; Arnell PM; Amin MB; Young RH
Mod Pathol; 2005 Jan; 18(1):19-25. PubMed ID: 15389251
[TBL] [Abstract][Full Text] [Related]
16. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.
Vang R; Gown AM; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Ronnett BM
Am J Surg Pathol; 2006 Sep; 30(9):1130-9. PubMed ID: 16931958
[TBL] [Abstract][Full Text] [Related]
17. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
[TBL] [Abstract][Full Text] [Related]
18. Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation.
Park KJ; Bramlage MP; Ellenson LH; Pirog EC
Appl Immunohistochem Mol Morphol; 2009 Jan; 17(1):8-11. PubMed ID: 18776815
[TBL] [Abstract][Full Text] [Related]
19. PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.
Ates Ozdemir D; Usubutun A
Pathol Oncol Res; 2016 Jul; 22(3):593-9. PubMed ID: 26797858
[TBL] [Abstract][Full Text] [Related]
20. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray.
Kim MJ
J Korean Med Sci; 2005 Aug; 20(4):643-8. PubMed ID: 16100458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]